NEW YORK (GenomeWeb News) — Transgenomic today said that Italian molecular diagnostic shop Fiuotecnica will use its Wave technology to develop and market a genetic assay panel to predict the risk of cardiovascular disease and heart attacks.
 
Fiuotecnica will retain rights to market the panel in Italy and Transgenomic will obtain rights to market it in the rest of the world.
 
Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.